<DOC>
	<DOC>NCT00636545</DOC>
	<brief_summary>The primary objective is to determine the safety and maximum tolerated dose (MTD) of Genasense administered as a 2-hour intravenous infusion once weekly (Part 1) and twice weekly (Part 2) to patients with solid tumors.</brief_summary>
	<brief_title>Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Confirmed diagnosis of a solid tumor malignancy, not to include lymphoma, that has failed standard therapy or for which no standard therapy is available Adequate organ function as determined â‰¤ 7 days prior to starting study medication Eastern Cooperative Oncology Group performance status 0 to 2 At least 3 weeks and recovery from effects of major prior surgery or other therapy, including chemotherapy, radiation therapy, immunotherapy, or cytokine, biologic, or vaccine therapy Exclusion criteria Other significant medical disease History or presence of leptomeningeal disease Coexisting condition that would require the subject to continue therapy during the treatment phase of the study with a drug known to alter renal function Pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Genasense</keyword>
	<keyword>oblimersen</keyword>
	<keyword>antisense</keyword>
	<keyword>Bcl-2 antisense</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>